<DOC>
	<DOCNO>NCT01653561</DOCNO>
	<brief_summary>The hypothesis clinical research study discover study drug apatinib shrink slow growth pretreated non-triple-negative metastatic breast cancer .</brief_summary>
	<brief_title>A Study Apatinib Non-triple-negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Apatinib tyrosine kinase inhibitor target vascular endothelial growth factor receptor ( VEGFR ) , anti-angiogenesis effect view preclinical test . The investigator ' phase I study show drug 's toxicity manageable maximum tolerable daily dose 850 mg . The hypothesis clinical research study discover study drug apatinib shrink slow growth non-triple-negative breast cancer . The safety apatinib also study . Patients physical state , symptom , change size tumor , laboratory finding obtain on-study help research team decide apatinib safe effective pretreated non-triple-negative metastatic breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>●≥ 18 ≤ 70 year age . ECOG performance status 01 . Metastatic breast cancer , confirm histological analysis . Have experience least 1 4 regimen , fail last chemotherapy regimen . Pretreated anthracycline , taxanes capecitabine ( rational reason use capecitabine acceptable ) mandatory . Women diagnose human epidermal growth factor receptor positive ( HER2+ ) fail least 1 antiHER2 therapy ( rational reason use antiHER2 therapy acceptable ) . HER2+ define +++ stain immunohistochemistry FISH/CISH positive gene amplification . Women diagnose HR+ fail least 1 hormonal therapy . Have fail least one chemotherapy regimen , three regimen ( include adjuvant neoadjuvant setting ) . Duration last therapy ( chemotherapy , radiotherapy , target therapy operation ) 4 week ( Duration nitroso mitomycin 6 week ) . Have least one extracranial measurable site disease accord RECIST 1.0 criterion previously irradiate . Life expectancy 3 month . Negative serum urine pregnancy test take woman within 7 day inclusion . Sexually active woman childbearing potential must use medically acceptable form contraception begin study 8 week last dose investigated drug . Written inform consent prior study specific screening procedure . Triplenegative breast cancer ( ER , PR HER2 . HER2 define 0 1+ stain immunohistochemistry FISH/CISH negative gene amplification . ) Pregnant lactate woman . Less 4 week last clinical trial . Uncontrolled hypertension monodrug therapy ( ＞140/90 mm Hg ) ；ischemia myocardium （≥ grade 2） myocardial infarction；arrhythmia（≥ grade 2 , QTcF ＞ 470ms female patients） New York Heart Association Class III/IV Any factor influence usage oral administration . The cumulative dos doxorubicin epirubicin inclusion surpass 300 mg/m2 600 mg/m2 , respectively . Duration last therapy ( chemotherapy , radiotherapy , target therapy operation ) less 4 week ( Duration nitroso mitomycin less 6 week ) . Confirmed brain metastasis . Inadequate hepatic , renal , heart , hematologic function ( hemoglobin ＜90g/L , neutrophils ＜ 1.5×10^9/L , platelet ＜ 80×10^9/L , ALT ＞ 2.5 x upper limit normal ( ULN ) ( 5x liver metastasis ) , AST ＞ 2.5 x ULN ( 5x liver metastasis ) , serum bilirubin ＞ 1.5 x ULN , serum creatine ＞ 1.0 x ULN , creatinine clearance rate ≤ 50ml/min , LVEF ＜ low limit normal ( LLN ) . Abnormal coagulative function , inclined bleed receive thrombolytictherapy anticoagulation . History arterial/venous embolic event ( cerebrovascular accident , TIA , deep vein thrombus , pulmonary embolism ) Unhealed wound ( ＞ 30 day ) bone fracture . Urine protein ≥++ confirm ＞1.0 g 24h quantity . Previous present history pulmonary fibrosis , interstitial pneumonia , pneumoconiosis , radiation pneumonitis , drugrelated pneumonitis greatlyimpaired pulmonary function . Disability serious uncontrolled intercurrence infection . Abuse alcohol drug . Have receive prior treatment VEGFR , PDGFR sSRC TKI ( Bevacizumab permit ) . Acquired inherent immunodeficiency； HIV infection； organ transplantation history . The active HBV HCV infection HBV DNA ≥10^4/ml . History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix . Presence serious harm subject complication hinder completion study judge investigator</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Apatinib</keyword>
	<keyword>non-triple-negative</keyword>
</DOC>